Table 2 Baseline demographics, apolipoprotein E status, cerebrospinal fluid markers and clinical score evolution in the longitudinal cohort (patients with significant memory complaint/mild cognitive impairment) by last known status

Follow-up duration, months

25 ± 12

34 ± 16^a

36 ± 13

Male sex

40 (38%)

121 (58%)^a

43 (52%)

Age, years

71 ± 6

72 ± 7

73 ± 7

ApoE4 carriers

41 (39%)

87 (42%)

58 (71%)^b

 GDS

1.1 ± 1.1

1.8 ± 1.4^a

1.8 ± 14

 MMSE

29 ± 1

28 ± 2^a

27 ± 2^b

 CDR 0

86 (82%)

9 (4%)^a

1 (1%)^b

 CDR 0.5

19 (18%)

199 (95%)^a

81 (99%)^b

 CDR ≥1

0

1 (0.5%)

0

 ADAS-cog

9 ± 4

14 ± 6^a

22 ± 7^b

 Aβ_1–42 (ng/L)

204 ± 48

179 ± 53^a

141 ± 35^b

 Tau (ng/L)

62 ± 30

77 ± 44^a

121 ± 60^b

 p-Tau₁₈₁ (ng/L)

35 ± 20

38 ± 23

59 ± 25^b

 p-Tau₁₈₁/Aβ_1–42

0.19 ± 0.15

0.25 ± 0.20^c

0.44 ± 0.21^b

 MMSE annual change

−0.1 ± 0.2

−0.4 ± 1.1

−2 ± 2.3^b

 CDR annual change

0.01 ± 0.14

0.00 ± 0.10

0.23 ± 0.21^b

 ADAS-cog annual change

−0.1 ± 2.3

0.5 ± 3.3

3.7 ± 3.8^b

 Time to conversion, months

–

–

22 ± 13